The DARK Reality Behind 'Gender Affirming Care' - Keira Bell (#2)
28 February 2025
With Keira Bell
UK
Keira Bell was prescribed puberty blockers at sixteen and testosterone at eighteen at the Tavistock Gender Identity Development Service. After detransitioning, she brought a landmark legal challenge that led the High Court to question whether children could consent to such treatments. Although that ruling was later overturned on appeal, the scrutiny it generated contributed directly to the Cass Review's devastating assessment of NHS gender services and the closure of Tavistock's GIDS in 2024. This episode examines what her case established in law and evidence, and what it means for paediatric gender medicine across Europe.
Keira Bell's story sits at the intersection of lived experience and institutional accountability. She was referred to the Tavistock Gender Identity Development Service as a teenager, prescribed puberty blockers at sixteen and testosterone at eighteen. After years on a medical pathway she later came to regret, she detransitioned — and then did something rare: she turned her personal history into a legal challenge that forced British courts to examine whether children could meaningfully consent to treatments whose long-term consequences were, by the clinic's own admission, poorly understood. The case of Bell v Tavistock reached the High Court in 2020 and produced a landmark ruling that cast serious doubt on the capacity of under-sixteens to provide informed consent to puberty-suppressing medication. The judgment drew on the absence of robust evidence for the treatments' safety and efficacy, and on the experimental nature of their use in a paediatric population. The Court of Appeal overturned that ruling in 2021, but the legal scrutiny the case had generated already set in motion a broader institutional reckoning within NHS gender services. That reckoning arrived in full with the Cass Review, an independent examination of NHS gender services commissioned by NHS England. Its final report, published in 2024, found the evidence base underpinning puberty blockers and cross-sex hormones for adolescents to be of remarkably poor quality. It concluded that the Tavistock service had failed to adequately assess its patients, had not followed them up rigorously, and had adopted an affirmative clinical model without the scrutiny that would be expected of any other paediatric intervention. The Tavistock GIDS closed the same year. The implications have extended well beyond England. Health authorities and regulators across Scandinavia and elsewhere in Europe had already begun reviewing or restricting paediatric gender medicine before the Cass Review was finalised, and Bell's case contributed to a climate in which those reviews became institutionally possible. Several countries have since cited the need for rigorous evidence before exposing young people to interventions with potentially irreversible effects — a standard the Tavistock pathway was found not to have met. In this conversation with Stella O'Malley and Bret Alderman, Keira Bell speaks about the personal cost of what she underwent, her experience of challenging a major NHS institution through the courts, and what she believes the Tavistock closure and the Cass Review's findings mean for young people still seeking help. Her account adds something that systematic reviews and court transcripts cannot provide: a first-person record of what it meant to be on the receiving end of a clinical pathway later found wanting by the very standards of evidence-based medicine it claimed to follow.
